Lili Ma

Lili Ma

Auto-generated profile, based on publicly available information

Lili Ma

College of Chemistry and Materials Science, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Chemical Biology Key Laboratory of Hebei Province, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Hebei University, Baoding 071002, PR China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Inorganic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
LMLili Ma
Lili Ma
LLLuwei Li
Luwei Li
Guangyu ZhuGuangyu Zhu
Guangyu Zhu
Platinum-based anticancer drugs are among the most widely used antineoplastics in clinical settings. Their therapeutic applications and outcomes are, however, greatly hampered by drug resistance, systemic toxicity, and the lack of antimetastatic and diagnostic properties. The incorporation of second metal centers with distinct biological targets and favorable physical and chemical properties into platinum complexes is a promising strategy to improve the anticancer efficacy of platinum drugs and overcome their shortcomings. This review focuses on Pt-containing heterometallic complexes Pt–M (M = Ru, Au, Ti, Fe, Rh, Pd, Cu, Ir, Gd, Eu, Re, and Tc) for cancer therapy. The design, anticancer activities, mechanism of action, and interplay between Pt and the second metal center are discussed. Many dual-pharmacophore heterometallic complexes have shown a great potential for overcoming cisplatin resistance. Besides, the incorporation of Ru(III) or areneRu(II) moieties into Pt complexes has been proved to inhibit cancer metastasis effectively. Moreover, theragnostic heterometallic complexes have been obtained by combining cytotoxic Pt and luminescent Eu(III), MRI responsive Gd(III), or radioactive 99mTc(I) into a single molecule. We also discuss the photophysical and bioimaging properties of theragnostic heterometallic complexes. This review provides a comprehensive landscape of representative examples of Pt-containing heterometallic complexes investigated in the last decade for cancer therapy and may guide researchers in exploring the challenges and opportunities in this emerging field.

14 June 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
LMLili Ma
Lili Ma
NWNa Wang
Na Wang
RMRong Ma
Rong Ma
CLCai Li
Cai Li
ZXZoufeng Xu
Zoufeng Xu
Guangyu ZhuGuangyu Zhu
Guangyu Zhu

2 August 2016 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
LMLili Ma
Lili Ma
RMRong Ma
Rong Ma
ZWZhigang Wang
Zhigang Wang
SYShek-Man Yiu
Shek-Man Yiu
Guangyu ZhuGuangyu Zhu
Guangyu Zhu
Putting spear and shield together: heterodinuclear Pt( iv )–Ru( ii ) complexes effectively and quickly kill cisplatin-resistant cancer cells and impede cancer cell migration.

13 February 2018 in Inorganic Chemistry
Verified
Journal Article
Closed access
LMLili Ma
Lili Ma
XLXudong Lin
Xudong Lin
CLCai Li
Cai Li
ZXZoufeng Xu
Zoufeng Xu
CCChun-Yin Chan
Chun-Yin Chan
Guangyu ZhuGuangyu Zhu
Guangyu Zhu

30 March 2015 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
RMRong Ma
Rong Ma
YWYiping Wang
Yiping Wang
LYLi Yan
Li Yan
LMLili Ma
Lili Ma
ZWZhigang Wang
Zhigang Wang
Guangyu ZhuGuangyu Zhu
Guangyu Zhu
Co-delivery of a Pt( iv ) prodrug and a p53 activator using layered double hydroxide (LDH) nanoparticles results in a significantly improved cell-killing effect.

4 November 2016 in European Journal of Inorganic Chemistry
Verified
Journal Article
Open access
PDF file
ZXZoufeng Xu
Zoufeng Xu
CLCai Li
Cai Li
ZTZixuan Tong
Zixuan Tong
LMLili Ma
Lili Ma
MTMan‐Kit Tse
Man‐Kit Tse
Guangyu ZhuGuangyu Zhu
Guangyu Zhu
Compared with square‐planar PtII drugs, PtIV‐based anticancer prodrugs are relatively inert under physiological conditions and can be activated after entering cells. The two axial ligands in PtIV complexes provide an opportunity to further functionalize these prodrugs. In recent years, much effort has been devoted to developing new PtIV‐based anticancer prodrugs with higher cytotoxicity but fewer side effects. New synthetic methods, however, are intensely desired for structurally diversified and biologically distinct PtIV complexes. Herein, we utilize N‐halosuccinimides as oxidants and carry out the oxidation reaction on PtII drugs including cisplatin, carboplatin, and oxaliplatin to obtain halogenated PtIV complexes. The related mechanism of the reaction of N‐bromosuccinimide (NBS) with cisplatin in ethanol is thoroughly investigated. N‐chlorosuccinimide is also utilized to obtain the respective dichlorinated PtIV complexes. When N‐iodosuccinimide reacts with PtII drugs, new PtIV compounds containing iodide and succinimide ligands in the axial position are formed. Cytotoxicity test shows that some of the complexes are active against cisplatin‐resistant human ovarian cancer cells. Our study provides a detailed understanding of the reaction mechanism between NBS and cisplatin and offers a more convenient strategy to obtain dichlorinated and new iodinated PtIV anticancer prodrugs.